Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
{{output}}
Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs ag... ...
